Evidence map›Paper›PMID 33811057›Full record

ArticleBMJ open2021

Erector spinae plane block for minimally invasive mitral valve surgery: a double-blind, prospective, randomised placebo-controlled trial-a study protocol.

Danny Feike Hoogma, Steffen Rex, Jos Tournoy, Peter Verbrugghe, Steffen Fieuws, Layth Al Tmimi

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Danny Feike HoogmaDepartment of Anaesthesiology, KU Leuven University Hospitals Leuven, Leuven, Belgium danny.hoogma@uzleuven.be.ORCID 0000-0002-9224-8198
Steffen RexDepartment of Anaesthesiology, KU Leuven University Hospitals Leuven, Leuven, Belgium.
Jos TournoyGeriatric Medicine, Department of Public Health and Primary Care, KU Leuven University Hospitals Leuven, Leuven, Belgium.
Peter VerbruggheDepartment of Cardiovascular Sciences, KU Leuven Biomedical Sciences Group, Leuven, Belgium.
Steffen FieuwsDepartment of Public Health and Primary Care, I-BioStat, KU Leuven Biomedical Sciences Group, Leuven, Belgium.
Layth Al TmimiDepartment of Anaesthesiology, KU Leuven University Hospitals Leuven, Leuven, Belgium.
KU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn the context of enhanced recovery after cardiac surgery, surgical techniques for mitral valve surgery have witnessed substantial modifications, from approaching the heart using open approaches with traditional sternotomy to thoracoscopic access via minithoracotomy. After cardiac surgery, acute postoperative pain is frequent and caused by surgical incision and retraction. Perioperative analgesia in cardiac surgery still relies mainly on opioids. Although neuraxial techniques could be a valuable non-opioid-based analgesia regimen, they can be associated with devastating complications in situations with (iatrogenic) coagulation abnormalities. Only two randomised clinical trials describe the erector spinae plane (ESP) block to provide sufficient postoperative analgesia following cardiac surgery with median sternotomy. Regarding postoperative analgesia after cardiac surgery with a minithoracotomy approach, adequately designed trials are still lacking. We, therefore, designed a double-blind, placebo-controlled trial to prove the hypothesis that the ESP block reduces opioid consumption in patients undergoing minimally invasive mitral valve surgery (MIMVS). METHODS AND ANALYSIS: Sixty-four patients undergoing MIMVS will be included in this double-blind, prospective, placebo-controlled trial. Patients will be randomised to receive an ESP block with a catheter with either intermittent ropivacaine 0.5% (ropi group) or normal saline 0.9% (placebo group). Both groups will receive patient-controlled intravenous analgesia with morphine following extubation. Primary endpoint is the 24-hour cumulative morphine consumption after extubation. Multiple secondary endpoints will be evaluated. ETHICS AND DISSEMINATION: The study is approved by the ethics committee of the University Hospitals Leuven, the Clinical Trials Centre of the University Hospitals Leuven and the 'Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten'. Dissemination of the study results will be via scientific papers. TRIAL REGISTRATION NUMBER: EudraCT identifier: 2019-001125-27.

Indexed as

Cardiac Surgical ProceduresNerve BlockAnalgesics, OpioidDouble-Blind MethodHumansMitral ValvePostoperative PainProspective StudiesRandomized Controlled Trials as TopicAnalgesics, Opioidadult anaesthesiaanaesthesia in cardiologycardiac surgerypain management

Identifiers

PMID33811057
PMCPMC8023758
OpenAlexW3151387232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.